TIGIT signalling pathway negatively regulates CD4+ T-cell responses in systemic lupus erythematosus

Immunology

Volumn 151, Issue 3, 2017, Pages 280-290

  Mao, Lie ^a   Hou, Hongyan ^a   Wu, Shiji ^a   Zhou, Yu ^a   Wang, Juan ^a   Yu, Jing ^a   Wu, Xiaohui ^a   Lu, Yanfang ^a   Mao, Liyan ^a   Bosco, Munyemana Jean ^a   Wang, Feng ^a   Sun, Ziyong ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

CD4+ T cells; systemic lupus erythematosus; therapeutic target; TIGIT

Indexed keywords

ANTIGEN; C REACTIVE PROTEIN; CD155 ANTIGEN; CD4 ANTIGEN; IMMUNOGLOBULIN G; RECEPTOR ANTIBODY; T LYMPHOCYTE ANTIBODY; T LYMPHOCYTE IMMUNOGLOBULIN AND ITIM DOMAIN; UNCLASSIFIED DRUG; BIOLOGICAL MARKER; IMMUNOGLOBULIN RECEPTOR; POLIOVIRUS RECEPTOR; T CELL IG AND ITIM DOMAIN PROTEIN, MOUSE; TIGIT PROTEIN, HUMAN; VIRUS RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE ACTIVITY; DOWN REGULATION; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; KIDNEY TISSUE; LYMPHADENOPATHY; LYMPHOCYTE FUNCTION; LYMPHOCYTE PROLIFERATION; MAJOR CLINICAL STUDY; MOLECULAR PATHOLOGY; MOUSE; NATURAL KILLER CELL; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PHENOTYPE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TARGETING; SIGNAL TRANSDUCTION; SLEDAI; SPLEEN TISSUE; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE ACTIVATION; THERAPY DELAY; ANIMAL; CASE CONTROL STUDY; CELL CULTURE; CELL PROLIFERATION; DISEASE MODEL; IMMUNOLOGY; LUPUS ERYTHEMATOSUS, SYSTEMIC; LYMPHOCYTE ACTIVATION; METABOLISM; MURPHY ROTHS LARGE LYMPHOPROLIFERATIVE MOUSE; TIME FACTOR; UPREGULATION;

ANIMALS; BIOMARKERS; CASE-CONTROL STUDIES; CD4-POSITIVE T-LYMPHOCYTES; CELL PROLIFERATION; CELLS, CULTURED; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; LYMPHOCYTE ACTIVATION; MICE, INBRED MRL LPR; PHENOTYPE; RECEPTORS, IMMUNOLOGIC; RECEPTORS, VIRUS; SIGNAL TRANSDUCTION; TIME FACTORS; UP-REGULATION;

EID: 85013481715     PISSN: 00192805     EISSN: 13652567     Source Type: Journal    
DOI: 10.1111/imm.12715     Document Type: Article

References (43)

1. Rahman A, Isenberg DA. Mechanisms of disease: systemic lupus erythematosus. N Engl J Med 2008; 358:929–39.
2. Zubler RH, Miescher PA. Role of T lymphocytes in systemic lupus erythematosus. Ann Med Interne (Paris) 1990; 141:208–12.
3. Abbas AK, Murphy KM, Sher A. Functional diversity of helper T lymphocytes. Nature 1996; 383:787–93.
4. Shlomchik MJ, Craft JE, Mamula MJ. From T to B and back again: positive feedback in systemic autoimmune disease. Nat Rev Immunol 2001; 1:147–53.
5. Mak A, Kow NY. The pathology of T cells in systemic lupus erythematosus. J Immunol Res 2014; 2014:419029.
6. Boles KS, Vermi W, Facchetti F, Fuchs A, Wilson TJ, Diacovo TG et al. A novel molecular interaction for the adhesion of follicular CD4 T cells to follicular DC. Eur J Immunol 2009; 39:695–703.
7. Joller N, Hafler JP, Brynedal B, Kassam N, Spoerl S, Levin SD et al. Cutting edge: TIGIT has T cell-intrinsic inhibitory functions. J Immunol 2011; 186:1338–42.
8. Yu X, Harden K, Gonzalez LC, Francesco M, Chiang E, Irving B et al. The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells. Nat Immunol 2009; 10:48–57.
9. Levin SD, Taft DW, Brandt CS, Bucher C, Howard ED, Chadwick EM et al. Vstm3 is a member of the CD28 family and an important modulator of T-cell function. Eur J Immunol 2011; 41:902–15.
10. Joller N, Lozano E, Burkett PR, Patel B, Xiao S, Zhu C et al. Treg cells expressing the coinhibitory molecule TIGIT selectively inhibit proinflammatory Th1 and Th17 cell responses. Immunity 2014; 40:569–81.
11. Kurtulus S, Sakuishi K, Ngiow SF, Joller N, Tan DJ, Teng MW et al. TIGIT predominantly regulates the immune response via regulatory T cells. J Clin Invest 2015; 125:4053–62.
12. Godefroy E, Zhong H, Pham P, Friedman D, Yazdanbakhsh K. TIGIT-positive circulating follicular helper T cells display robust B-cell help functions: potential role in sickle cell alloimmunization. Haematologica 2015; 100:1415–25.
13. Stanietsky N, Simic H, Arapovic J, Toporik A, Levy O, Novik A et al. The interaction of TIGIT with PVR and PVRL2 inhibits human NK cell cytotoxicity. Proc Natl Acad Sci USA 2009; 106:17858–63.
14. + T cells during recurrence of melanoma. J Immunol 2013; 190:4899–909.
15. Stengel KF, Harden-Bowles K, Yu X, Rouge L, Yin J, Comps-Agrar L et al. Structure of TIGIT immunoreceptor bound to poliovirus receptor reveals a cell–cell adhesion and signaling mechanism that requires cis-trans receptor clustering. Proc Natl Acad Sci USA 2012; 109:5399–404.
16. Zhao W, Dong Y, Wu C, Ma Y, Jin Y, Ji Y. TIGIT overexpression diminishes the function of CD4 T cells and ameliorates the severity of rheumatoid arthritis in mouse models. Exp Cell Res 2016; 340:132–8.
17. + T cell effector function. Cancer Cell 2014; 26:923–37.
18. Wang F, Hou H, Wu S, Tang Q, Liu W, Huang M et al. TIGIT expression levels on human NK cells correlate with functional heterogeneity among healthy individuals. Eur J Immunol 2015; 45:2886–97.
19. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25:1271–7.
20. Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH. Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum 1992; 35:630–40.
21. Chan CJ, Martinet L, Gilfillan S, Souza-Fonseca-Guimaraes F, Chow MT, Town L et al. The receptors CD96 and CD226 oppose each other in the regulation of natural killer cell functions. Nat Immunol 2014; 15:431–8.
22. Freeman GJ, Long AJ, Iwai Y, Bourque K, Chernova T, Nishimura H et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med 2000; 192:1027–34.
23. O'Neill S, Cervera R. Systemic lupus erythematosus. Best Pract Res Clin Rheumatol 2010; 24:841–55.
24. Danchenko N, Satia JA, Anthony MS. Epidemiology of systemic lupus erythematosus: a comparison of worldwide disease burden. Lupus 2006; 15:308–18.
25. Fessel WJ. Systemic lupus erythematosus in the community. Incidence, prevalence, outcome, and first symptoms; the high prevalence in black women. Arch Intern Med 1974; 134:1027–35.
26. Robak E, Robak T. Novel and emerging drugs for systemic lupus erythematosus: mechanism of action and therapeutic activity. Curr Med Chem 2012; 19:438–53.
27. + T cells of systemic lupus erythematosus. J Autoimmun 2013; 41:92–9.
28. + T-cell populations. PLoS Genet 2013; 9:e1003678.
29. + T cells from patients with systemic lupus erythematosus, systemic sclerosis, and dermatomyositis. Scand J Rheumatol 2009; 38:369–74.
30. + T cell activation and B cell hyperstimulation in systemic lupus erythematosus. Arthritis Rheum 2012; 64:2953–63.
31. Yan S, Yim LY, Lu L, Lau CS, Chan VS. MicroRNA regulation in systemic lupus erythematosus pathogenesis. Immune Netw 2014; 14:138–48.
32. + T cells and contributes to systemic lupus erythematosus by targeting DNA methyltransferase 1. Arthritis Rheum 2011; 63:1376–86.
33. Yellin MJ, Thienel U. T cells in the pathogenesis of systemic lupus erythematosus: potential roles of CD154-CD40 interactions and costimulatory molecules. Curr Rheumatol Rep 2000; 2:24–31.
34. Zha Y, Blank C, Gajewski TF. Negative regulation of T-cell function by PD-1. Crit Rev Immunol 2004; 24:229–37.
35. Zhu C, Anderson AC, Kuchroo VK. TIM-3 and its regulatory role in immune responses. Curr Top Microbiol Immunol 2011; 350:1–15.
36. Song LJ, Wang X, Wang XP, Li D, Ding F, Liu HX et al. Increased Tim-3 expression on peripheral T lymphocyte subsets and association with higher disease activity in systemic lupus erythematosus. Diagn Pathol 2015; 10:71.
37. + T cells is associated with higher IFN-γ production and altered IL-17 production in patients with systemic lupus erythematosus. Scand J Rheumatol 2014; 43:307–13.
38. Wofsy D, Seaman WE. Reversal of advanced murine lupus in NZB/NZW F1 mice by treatment with monoclonal antibody to L3T4. J Immunol 1987; 138:3247–53.
39. Molina JF, Citera G, Rosler D, Cuellar ML, Molina J, Felipe O et al. Coexistence of human immunodeficiency virus infection and systemic lupus erythematosus. J Rheumatol 1995; 22:347–50.
40. Desai-Mehta A, Mao C, Rajagopalan S, Robinson T, Datta SK. Structure and specificity of T cell receptors expressed by potentially pathogenic anti-DNA autoantibody-inducing T cells in human lupus. J Clin Invest 1995; 95:531–41.
41. + T cells ameliorates immune-mediated bone marrow failure of aplastic anemia. J Cell Biochem 2014; 115:1918–27.
42. + T cell responses. Oncoimmunology 2015; 4:e1036214.
43. Chew GM, Fujita T, Webb GM, Burwitz BJ, Wu HL, Reed JS et al. TIGIT marks exhausted T cells, correlates with disease progression, and serves as a target for immune restoration in HIV and SIV infection. PLoS Pathog 2016; 12:e1005349.